drugset / Trial / NCT02171000

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

NCT02171000

Phase 1 Completed 7 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To investigate safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of multiple doses (150 mg b.i.d., 7 days)

Timeline

Start
2005-04
Primary completion
2005-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral

Indications

No indication recorded.